Developing breakthrough platforms for long acting non-viral
gene therapy for ocular diseases

Eyevensys S.A.S. is a privately held biotechnology company developing combinations of long acting therapeutic technology platforms together with proteins for the treatment of ocular diseases.

The most advanced technology is a breakthrough non-viral gene therapy combined with electrotransfer of the ciliary muscle for ocular diseases.

The initial targeted indications are

• Uveitis, cause of 10% of blindness in the world
• Age-related Macular Degeneration (AMD), the leading cause of non-correctable blindness in the Western World. It is thought to affect up to 12% of people aged 65-75. In ageing populations the incidence of the disease is expected to increase almost 50% by 2020. Worldwide an estimated 25 million people are affected.

Eyevensys is the only company to have reached this advanced stage of investigation in novel treatment approaches to non-viral gene therapy expected to meet critical ophthalmology unmet needs such as less frequent administration (every four to six months), easier access, improved tolerability and compliance. As a consequence, on mid-long term efficacy end points are expected to be improved.

News

Eyevensys S.A.S. Presents at BioTrinity 2014 - European Biopartnering and Investment Conference

22-05-2014

Eyevensys S.A.S. Presents at BioTrinity 2014 - European Biopartnering and Inves...

Eyevensys S.A.S. Presents at BioEquity Europe 2014

14-05-2014

Eyevensys S.A.S. Presents at BioEquity Europe 2014, May-21-2014 04:50 PM. Venue...

Eyevensys Appoints Raffy Kazandjian as CEO

28-03-2014

Eyevensys S.A.S. announced the appointment of Mr. Raffy Kazandjian as CEO. ...